Brokerages Set Omeros Co. (NASDAQ:OMER) PT at $22.50

Shares of Omeros Co. (NASDAQ:OMER) have earned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $22.50.

A number of research analysts have weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Friday, January 17th. D. Boral Capital restated a “buy” rating and issued a $36.00 price objective on shares of Omeros in a report on Thursday, February 20th. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Rodman & Renshaw initiated coverage on Omeros in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a report on Thursday, November 14th.

Omeros Stock Performance

Omeros stock opened at $8.01 on Friday. The company’s fifty day moving average price is $8.90 and its 200 day moving average price is $7.12. Omeros has a 1 year low of $2.61 and a 1 year high of $13.60. The stock has a market capitalization of $464.18 million, a P/E ratio of -3.47 and a beta of 2.03.

Hedge Funds Weigh In On Omeros

Institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC grew its position in shares of Omeros by 121.3% during the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock worth $376,000 after buying an additional 51,873 shares in the last quarter. State Street Corp lifted its stake in Omeros by 0.3% during the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after purchasing an additional 3,839 shares during the last quarter. HighTower Advisors LLC lifted its stake in Omeros by 7.2% during the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock worth $235,000 after purchasing an additional 4,000 shares during the last quarter. Wellington Management Group LLP purchased a new stake in Omeros during the third quarter worth approximately $305,000. Finally, MML Investors Services LLC lifted its stake in Omeros by 19.2% during the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 3,000 shares during the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.